Find the latest pharmaceutical market place for formulations enquiry about Pasireotide on PharmaCompass.com.

Tender// Various Finished Dosage Formulations needed in Norway [ENA09768]

The Norwegian Hospital Procurement Trust is looking for supplies of Various Finished Dosage Formulations. The deadline is 16-March-2021.
1. Pegvisomant (25 mg, 30 mg, 15 mg, 20 mg and 10 mg) Powder and Solvent for Solution for Injection. The required quantity is 33 units, 64 units, 70 units, 108 units and 118 units respectively.
2. Octreotide (10 mg, 20 mg and 30 mg) Powder and Liquid for Depot Injection. The required quantity is 80 units, 252 units and 1328 units respectively.
3. Octreotide (10 mg, 20 mg and 30 mg) Powder and Solvent for Solution for Injection. The required quantity is 486 units, 1060 units and 2998 units respectively.
4. Octreotide (50 mcg/ ml, 200 mcg/ ml and 100 mcg/ ml) Injection/ Infusion Solution. The required quantity is 686 units, 2812 units and 3081 units respectively.
5. Lanreotide (60 mg/ spr, 90 mg/ spr and 120 mg/ spr) Solution for Injection. The required quantity is 27 units, 321 units and 4950 units respectively.
6. Pasireotide (10 mg, 20 mg, 60 mg and 40 mg) Powder and Solvent for Solution for Injection. The required quantity is 6 units, 10 units, 20 units and 112 units respectively.
7. Pasireotide (0.6 mg/ ml) Solution for Injection. The required quantity is 7 units.

Reply

19 Feb 2021